TScan Therapeutics's three largest insider shareholders as of April 17, 2026 are Capital Management Lp Lynx1 (TenPercentOwner, 8.02Mn shares), Capital Management Lp Lynx1 (TenPercentOwner, 7.94Mn shares), Capital Management Lp Lynx1 (TenPercentOwner, 5.24Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Capital Management Lp Lynx1 | - | 0 | 8,019,148 | 23 Dec, 2025 |
| Capital Management Lp Lynx1 | - | 0 | 7,937,416 | 23 Dec, 2025 |
| Capital Management Lp Lynx1 | - | 0 | 5,240,000 | 02 Jun, 2023 |
| Capital Management Lp Lynx1 | - | 0 | 5,225,547 | 19 Nov, 2024 |
| Bros. Advisors Lp Baker | - | 0 | 2,528,583 | 12 May, 2022 |
| Christoph H Westphal | - | 0 | 1,278,838 | 22 Jul, 2021 |
| David P Southwell | Chief Executive Officer | 171,569 | 0 | 20 May, 2022 |
| Timothy J Barberich | - | 67,027 | 0 | 21 Dec, 2023 |
| Gavin Macbeath | Chief Scientific Officer | 49,767 | 0 | 22 Sep, 2021 |
| Barbara Klencke | - | 45,000 | 0 | 24 Sep, 2024 |
| Brian M. Silver | Chief Financial Officer | 32,885 | 0 | 29 Dec, 2022 |
| Zoran Zdraveski | Chief Legal Officer | 4,716 | 0 | 27 Aug, 2024 |
| William Desmarais | Chief Business Officer | 2,500 | 0 | 31 Aug, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 20 Jan, 2026 | Chrystal Louis | Stock Option (Right to Buy) | A | 420,000 | $0.00 | 420,000 | D | A |
| 20 Jan, 2026 | Zoran Zdraveski | Stock Option (Right to Buy) | A | 350,000 | $0.00 | 350,000 | D | A |
| 20 Jan, 2026 | Leiden Dworak | Stock Option (Right to Buy) | A | 100,000 | $0.00 | 100,000 | D | A |
| 20 Jan, 2026 | Jason Amello | Stock Option (Right to Buy) | A | 350,000 | $0.00 | 350,000 | D | A |
| 20 Jan, 2026 | Gavin Macbeath | Stock Option (Right to Buy) | A | 1,165,000 | $0.00 | 1,165,000 | D | A |
| 19 Dec, 2025 | Capital Management Lp Lynx1 | Common stock, $0.0001 par value per share (Common Stock) | A | 80,069 | $0.90 | 7,937,416 | I | P |
| 22 Dec, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 75,500 | $0.90 | 8,012,916 | I | P |
| 23 Dec, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 6,232 | $0.90 | 8,019,148 | I | P |
| 30 Jun, 2025 | Keith Woods | Stock Option (Right to Buy) | A | 67,000 | $0.00 | 67,000 | D | A |
| 30 Jun, 2025 | Gabriela Gruia | Stock Option (Right to Buy) | A | 67,000 | $0.00 | 67,000 | D | A |
| 30 Jun, 2025 | Katina Dorton | Stock Option (Right to Buy) | A | 67,000 | $0.00 | 67,000 | D | A |
| 30 Jun, 2025 | Barbara Klencke | Stock Option (Right to Buy) | A | 67,000 | $0.00 | 67,000 | D | A |
| 30 Jun, 2025 | Garry A Nicholson | Stock Option (Right to Buy) | A | 67,000 | $0.00 | 67,000 | D | A |
| 30 Jun, 2025 | Bros. Advisors Lp Baker | Non- Qualified Stock Option (right to buy) | A | 67,000 | $0.00 | 67,000 | I | A |
| 30 Jun, 2025 | Bros. Advisors Lp Baker | Non- Qualified Stock Option (right to buy) | A | 67,000 | $0.00 | 67,000 | I | A |
| 19 May, 2025 | Capital Management Lp Lynx1 | Common stock, $0.0001 par value per share (Common Stock) | A | 1,388,794 | $1.20 | 6,746,141 | I | P |
| 20 May, 2025 | Capital Management Lp Lynx1 | Common Stock | A | 1,200,000 | $1.20 | 7,946,141 | I | P |
| 03 Jan, 2025 | Jason Amello | Stock Option (Right to Buy) | A | 270,000 | $0.00 | 270,000 | D | A |
| 03 Jan, 2025 | Chrystal Louis | Stock Option (Right to Buy) | A | 400,000 | $0.00 | 400,000 | D | A |
| 26 Dec, 2024 | Capital Management Lp Lynx1 | Pre-funded Warrant (right to buy) | A | 7,500,000 | $4.00 | 7,500,000 | I | P |